Profile data is unavailable for this security.
About the company
XOMA Corporation is a biotechnology royalty aggregator. The Company’s royalty aggregator business is primarily focused on early to mid-stage clinical assets, primarily in Phase I and II, with significant commercial sales potential that are licensed to larger pharmaceutical partners. The Company has a portfolio of economic rights and royalty payments associated with partnered commercial and pre-commercial therapeutic candidates. Its royalty portfolio includes DAY101 (tovorafenib), JNJ-63723283 (cetrelimab), RZ358, arimoclomol, TAK-079 (mezagitamab), BAY-1213790 (osocimab), AFM13 (acimtamig), AB023 (gruticibart), AB002 (E-WE thrombin), AB054, AV-299 (ficlatuzumab), COM902, vosaroxin, aldoxorubicin, INCAGN2385, INCAGN02390, MNPR-101, PBF-680, PBF-677, PBF-999, PBF-1129, PBF-1650, G03-52-01, RZ402, DSUVIA (sufentanil sublingual tablet), IXINITY [coagulation factor IX (recombinant)], VABYSMO (faricimab-svoa), CMP-001 (vidutolimod), and CFZ533 (iscalimab).
- Revenue in USD (TTM)4.76m
- Net income in USD-46.30m
- Incorporated2011
- Employees13.00
- LocationXOMA CorpSuite 310, 2200 Powell StreetEMERYVILLE 94608United StatesUSA
- Phone+1 (510) 204-7239
- Fax+1 (302) 655-5049
- Websitehttps://www.xoma.com/
More ▼
Mergers & acquisitions
| Acquired company | XOMA:NMQ since announced | Transaction value |
|---|---|---|
| Kinnate Biopharma Inc | 10.87% | 99.33m |
Data delayed at least 15 minutes, as of Apr 18 2024 21:00 BST.
Peer analysis
Key Information
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Rapt Therapeutics Inc | 0.00 | -116.80m | 275.96m | 131.00 | -- | 1.86 | -- | -- | -3.05 | -3.05 | 0.00 | 4.27 | 0.00 | -- | -- | 0.00 | -53.15 | -46.30 | -57.90 | -49.97 | -- | -- | -- | -3,522.72 | -- | -- | 0.00 | -- | -100.00 | -- | -39.31 | -- | -20.31 | -- |
| Enanta Pharmaceuticals Inc | 73.62m | -138.24m | 279.89m | 145.00 | -- | 1.46 | -- | 3.80 | -6.56 | -6.56 | 3.50 | 9.07 | 0.1897 | -- | 4.79 | 507,737.90 | -35.63 | -14.56 | -40.03 | -15.62 | -- | -- | -187.77 | -54.96 | -- | -- | 0.0074 | -- | -8.07 | -17.45 | -9.91 | -- | 24.89 | -- |
| Invivyd Inc | 0.00 | -198.64m | 280.17m | 94.00 | -- | 1.46 | -- | -- | -1.81 | -1.81 | 0.00 | 1.61 | 0.00 | -- | -- | 0.00 | -64.88 | -- | -73.98 | -- | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | 17.68 | -- | -- | -- |
| Inozyme Pharma Inc | 0.00 | -71.17m | 282.92m | 59.00 | -- | 2.01 | -- | -- | -1.39 | -1.39 | 0.00 | 2.27 | 0.00 | -- | -- | 0.00 | -41.86 | -45.00 | -45.82 | -48.90 | -- | -- | -- | -- | -- | -- | 0.2417 | -- | -- | -- | -6.13 | -- | 2.85 | -- |
| Sutro Biopharma Inc | 153.73m | -106.79m | 284.59m | 302.00 | -- | 1.54 | -- | 1.85 | -1.79 | -1.79 | 2.56 | 2.45 | 0.3503 | -- | 7.12 | 509,043.00 | -24.34 | -25.48 | -29.77 | -29.75 | -- | -- | -69.47 | -113.71 | -- | -- | 0.0264 | -- | 126.84 | 31.96 | 10.41 | -- | 22.61 | -- |
| Chromadex Corp | 83.57m | -4.94m | 285.42m | 106.00 | -- | 9.99 | -- | 3.42 | -0.0659 | -0.0659 | 1.11 | 0.3795 | 1.53 | 2.25 | 21.38 | 788,396.30 | -9.06 | -42.11 | -14.00 | -65.14 | 60.76 | 59.68 | -5.91 | -30.64 | 1.70 | -- | 0.0008 | -- | 15.99 | 21.50 | 70.15 | -- | -36.66 | -- |
| Vanda Pharmaceuticals Inc. | 192.64m | 2.51m | 285.96m | 203.00 | 113.34 | 0.5248 | 51.81 | 1.48 | 0.0439 | 0.0439 | 3.35 | 9.47 | 0.3004 | 11.60 | 5.69 | 948,965.50 | 0.3912 | 6.61 | 0.4547 | 7.62 | 92.32 | 90.55 | 1.30 | 15.18 | 4.92 | -- | 0.00 | 0.00 | -24.27 | -0.0496 | -60.02 | -36.96 | -56.77 | -- |
| XOMA Corp | 4.76m | -46.30m | 286.11m | 13.00 | -- | 3.19 | -- | 60.13 | -4.04 | -4.04 | 0.4148 | 7.72 | -- | -- | -- | 366,000.00 | -- | -4.55 | -- | -4.94 | -- | -- | -858.15 | -31.87 | -- | -- | 0.583 | -- | -21.06 | -2.13 | -105.10 | -- | 23.16 | -- |
| Metagenomi Inc | 44.76m | -68.26m | 290.41m | 236.00 | -- | -- | -- | 6.49 | -1.82 | -1.82 | 1.19 | 5.73 | -- | -- | -- | 189,644.10 | -- | -- | -- | -- | -- | -- | -152.50 | -- | -- | -- | 0.00 | -- | 160.21 | -- | -56.57 | -- | -- | -- |
| Q32 Bio Inc | 1.16m | -112.96m | 290.84m | 7.00 | -- | 1.08 | -- | 251.59 | -35.17 | -35.17 | 0.3598 | 22.64 | 0.0074 | -- | -- | 165,142.90 | -55.64 | -34.98 | -62.45 | -37.92 | -- | -- | -7,532.87 | -971.76 | -- | -- | 0.00 | -- | -63.97 | -26.32 | -2,156.96 | -- | -60.90 | -- |
| Akebia Therapeutics Inc | 194.62m | -51.93m | 291.03m | 167.00 | -- | -- | -- | 1.50 | -0.2778 | -0.2778 | 1.04 | -0.1572 | 0.6512 | 2.22 | 4.89 | 1,165,407.00 | -17.37 | -37.42 | -28.19 | -56.00 | 78.76 | 69.13 | -26.68 | -82.25 | 1.03 | -7.64 | 8.46 | -- | -33.46 | -1.30 | 44.89 | -- | -- | -- |
| Verrica Pharmaceuticals Inc | 5.12m | -67.00m | 292.69m | 100.00 | -- | 14.81 | -- | 57.12 | -1.46 | -1.46 | 0.113 | 0.466 | 0.0811 | -- | 2.09 | 51,240.00 | -106.07 | -55.75 | -126.60 | -78.33 | 85.44 | -- | -1,307.48 | -754.94 | 4.49 | -51.74 | 0.6914 | -- | -43.27 | -- | -173.59 | -- | 5.65 | -- |
| Nautilus Biotechnology Inc | 0.00 | -63.68m | 292.73m | 167.00 | -- | 1.10 | -- | -- | -0.5103 | -0.5103 | 0.00 | 2.12 | 0.00 | -- | -- | 0.00 | -19.42 | -- | -19.91 | -- | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -9.93 | -- | -- | -- |
| Sanara Medtech Inc | 64.99m | -4.30m | 293.26m | 107.00 | -- | 6.47 | -- | 4.51 | -0.5219 | -0.5219 | 7.85 | 5.25 | 0.9635 | 1.90 | 8.37 | 607,381.70 | -6.58 | -17.73 | -8.17 | -22.07 | 87.92 | 88.08 | -6.83 | -17.13 | 1.04 | -18.75 | 0.1786 | -- | 41.77 | 61.93 | 45.79 | -- | 99.09 | -- |
| Terns Pharmaceuticals Inc | 0.00 | -90.21m | 296.75m | 66.00 | -- | 1.16 | -- | -- | -1.27 | -1.27 | 0.00 | 3.95 | 0.00 | -- | -- | 0.00 | -32.48 | -41.34 | -33.72 | -45.70 | -- | -- | -- | -31,010.30 | -- | -- | 0.00 | -- | -- | -- | -49.49 | -- | -26.60 | -- |
Data as of Apr 18 2024. Currency figures normalised to XOMA Corp's reporting currency: US Dollar USD
57.01%Per cent of shares held by top holders
| Holder | Shares | % Held |
|---|---|---|
| BVF Partners LPas of 31 Dec 2023 | 3.63m | 31.26% |
| Fidelity Management & Research Co. LLCas of 31 Dec 2023 | 1.09m | 9.35% |
| BlackRock Fund Advisorsas of 31 Dec 2023 | 450.49k | 3.88% |
| The Vanguard Group, Inc.as of 31 Dec 2023 | 414.19k | 3.56% |
| Stonepine Capital Management LLCas of 31 Dec 2023 | 250.00k | 2.15% |
| Opaleye Management, Inc.as of 31 Dec 2023 | 250.00k | 2.15% |
| Geode Capital Management LLCas of 31 Dec 2023 | 160.94k | 1.38% |
| Acuitas Investments LLCas of 31 Dec 2023 | 137.13k | 1.18% |
| SSgA Funds Management, Inc.as of 31 Dec 2023 | 124.42k | 1.07% |
| TLS Advisors LLCas of 31 Dec 2023 | 120.47k | 1.04% |
More ▼
Data from 31 Dec 2023 - 31 Dec 2023Source: FactSet Research Systems Inc.
